GO:0034752 cytosolic aryl hydrocarbon receptor complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034752 describes the cytosolic aryl hydrocarbon receptor complex, an inactive, ligand-free assembly of AhR, two HSP90 molecules, c-Src, and XAP2/AIP.
• The complex keeps AhR stable and poised for ligand binding; upon agonist binding, it transforms and translocates to the nucleus to regulate target genes such as CYP1A1.
• XAP2/AIP (ARA9) modulates agonist signaling by increasing cytosolic AhR levels and influencing complex dynamics.
• The complex is linked to cyclic nucleotide signaling through phosphodiesterases, expanding its regulatory reach beyond canonical dioxin responses.
• Dysregulation of AhR signaling is implicated in toxic responses, cancer, immune modulation, and metabolic disease, making the cytosolic complex a therapeutic target.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of cytosolic aryl hydrocarbon receptor complex components and their functions.
Description
The cytosolic aryl hydrocarbon receptor complex (GO:0034752) is a cellular component defined as an aryl hydrocarbon receptor complex found in the cytosol in which the ligand-binding subunit AhR is not bound to ligand; it consists of AhR, two molecules of HSP90, the protein kinase c-Src, and the immunophilin XAP2/AIP. This complex represents the resting, ligand-free state of AhR and is central to understanding how environmental agents such as dioxins and other agonists initiate signaling. Because the complex maintains AhR in a conformation competent for ligand binding and subsequent transformation, it is a focal point for mechanistic studies of dioxin toxicity and AhR biology. Researchers study GO:0034752 to define how AhR is held inactive, how it becomes activated, and how components such as XAP2/AIP and c-Src contribute to signaling outcomes. The complex also intersects with cyclic nucleotide signaling through phosphodiesterases, indicating broader regulatory roles beyond canonical xenobiotic responses. Emerging approaches to antagonize AhR highlight the therapeutic relevance of targeting the cytosolic complex and its activation steps.
cytosolic aryl hydrocarbon receptor complex At A Glance
| GO ID | GO:0034752 |
|---|---|
| GO term | cytosolic aryl hydrocarbon receptor complex |
| Ontology | cellular_component |
| Synonym | 9S-cytosolic aryl hydrocarbon (Ah) receptor non-ligand activated complex; cytosolic AHRC; cytosolic AhR complex |
| Major function | Maintains AhR in a ligand-free, stable, and ligand-responsive state in the cytosol |
| Key components | AhR, two HSP90 molecules, c-Src, XAP2/AIP |
| Subcellular location | Cytosol |
| Related process | AhR signaling, dioxin response, xenobiotic metabolism |
| Modulators | XAP2/AIP (ARA9) increases cytosolic AhR and modifies agonist signaling |
| Signaling crosstalk | Phosphodiesterases link the complex to cyclic nucleotide signaling |
What Is GO:0034752?
In our own words, GO:0034752 refers to the cytosolic aryl hydrocarbon receptor complex: a multiprotein assembly in the cytosol in which the aryl hydrocarbon receptor (AhR) is not bound to ligand. The complex includes AhR, two molecules of HSP90, the kinase c-Src, and the immunophilin XAP2/AIP. This ligand-free state is often called the 9S-cytosolic aryl hydrocarbon (Ah) receptor non-ligand activated complex, cytosolic AHRC, or cytosolic AhR complex.
Why Is cytosolic aryl hydrocarbon receptor complex Important in Cell Biology?
The cytosolic aryl hydrocarbon receptor complex is important because it defines the resting state of AhR, a ligand-activated transcription factor that mediates toxic and adaptive responses to environmental chemicals such as dioxins. Understanding this complex helps explain how AhR is stabilized, how ligand binding triggers transformation and nuclear translocation, and how target genes like CYP1A1 are induced. Because AhR signaling influences cancer, immunity, and metabolism, the cytosolic complex is a potential target for therapeutic antagonism and for mechanistic studies using CRISPR models.
• Defines the ligand-free, cytosolic state of AhR that is essential for regulated activation.
• Explains the molecular basis of dioxin toxicity and AhR-mediated gene induction.
• XAP2/AIP modulates cytosolic AhR levels and agonist signaling, affecting sensitivity to ligands.
• Links AhR biology to cyclic nucleotide signaling via phosphodiesterases.
• Provides a target for emerging AhR antagonists in disease contexts.
• Supports research on xenobiotic metabolism and CYP1A1 regulation.
• Relevant to cancer, immune regulation, and metabolic disorders.
• Enables precise CRISPR-based dissection of complex components.
• Helps interpret species differences and biased agonism in AhR signaling.
• Guides development of experimental models for dioxin response and AhR-targeted therapies.
Core Biology of GO:0034752
Assembly of the Ligand-Free Cytosolic Complex
In simple terms: The cell builds a ready-to-go receptor package in the cytosol before any ligand arrives.
The cytosolic aryl hydrocarbon receptor complex assembles in the cytosol with AhR as the ligand-binding subunit, two molecules of HSP90, the kinase c-Src, and the immunophilin XAP2/AIP. This assembly represents the non-ligand-activated state and is often referred to as the 9S-cytosolic Ah receptor complex. XAP2/AIP (also known as ARA9) modifies agonist signaling by increasing cytosolic AhR levels, thereby influencing the abundance of the complex.
Ligand Binding and Complex Transformation
In simple terms: When a ligand binds, the receptor changes shape and gets ready to move into the nucleus.
Upon binding of agonists such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or alpha-naphthoflavone, the cytosolic complex undergoes transformation, releasing HSP90 and other components, and AhR translocates to the nucleus. This transformation is a prerequisite for AhR to dimerize with ARNT and activate target genes like CYP1A1. Studies with alpha-naphthoflavone show that cytosolic AhR transformation correlates with CYP1A1 gene expression.
Crosstalk with Cyclic Nucleotide Signaling
In simple terms: The receptor complex talks to other signaling pathways that use cyclic nucleotides.
Phosphodiesterases link the aryl hydrocarbon receptor complex to cyclic nucleotide signaling, indicating that the cytosolic complex is not isolated but integrated with broader cellular signaling networks. This crosstalk may modulate the sensitivity or kinetics of AhR activation and downstream responses.
Regulation of Cytosolic AhR Levels
In simple terms: Helper proteins control how much receptor is available in the cytosol.
XAP2/AIP (ARA9) modifies agonist signaling through an increase in cytosolic aryl hydrocarbon receptor, suggesting that the immunophilin regulates the stability or accumulation of the cytosolic complex. This regulation can affect the magnitude of downstream responses to AhR ligands.
Downstream Gene Induction
In simple terms: Once activated, the receptor turns on genes that help the cell respond to the chemical.
Activation of the cytosolic complex leads to induction of genes such as CYP1A1 and cytosolic phospholipase A2 alpha, which are involved in xenobiotic metabolism and lipid signaling. In mouse hepatoma Hepa-1c1c7 cells, TCDD induces the cytosolic phospholipase A2 alpha gene via AhR, demonstrating a downstream transcriptional response originating from the cytosolic complex.
Key Genes Involved in GO:0034752 cytosolic aryl hydrocarbon receptor complex
The following genes and proteins are core components or direct regulators of the cytosolic aryl hydrocarbon receptor complex (GO:0034752).
| Gene | Major Role | Research Relevance |
|---|---|---|
| AHR | Ligand-binding subunit of the cytosolic complex; transcription factor upon activation | Central to dioxin toxicity and AhR signaling studies |
| HSP90AA1 | Chaperone that binds AhR in the cytosol; two molecules per complex | Maintains AhR stability and ligand responsiveness |
| HSP90AB1 | Chaperone isoform that can associate with AhR | Supports complex assembly and function |
| SRC | Protein kinase c-Src component of the cytosolic complex | Contributes to signaling crosstalk and complex integrity |
| AIP | Immunophilin XAP2/AIP; modulates cytosolic AhR levels | Regulates agonist signaling and complex abundance |
| ARNT | Dimerization partner of AhR after nuclear translocation | Required for target gene induction |
| CYP1A1 | AhR target gene; xenobiotic-metabolizing enzyme | Biomarker of AhR activation |
| PLA2G4A | Cytosolic phospholipase A2 alpha; induced by TCDD via AhR | Links AhR to lipid signaling |
| PDE | Phosphodiesterase family; links complex to cyclic nucleotide signaling | Modulates crosstalk with cAMP/cGMP pathways |
| HSP90 co-chaperones | Assist HSP90 function in complex assembly | Potential modulators of AhR stability |
| AhR antagonists (chemical tools) | Compounds that block AhR activation | Therapeutic development and mechanistic probes |
| Biased agonists | Ligands that differentially activate AhR pathways | Study of biased agonism in AhR signaling |
| Dioxin (TCDD) | Prototype agonist that activates AhR | Model ligand for complex transformation studies |
| alpha-Naphthoflavone | Agonist/antagonist depending on context; induces CYP1A1 | Probe for cytosolic AhR transformation |
| ARA9 (AIP) | Alternative name for XAP2/AIP | Modifies cytosolic AhR and agonist signaling |
| c-Src | Non-receptor tyrosine kinase in the complex | Potential mediator of AhR crosstalk |
| Hepa-1c1c7 cells | Mouse hepatoma model for AhR studies | Used to study TCDD-induced gene expression |
How Is cytosolic aryl hydrocarbon receptor complex Regulated?
The cytosolic aryl hydrocarbon receptor complex is regulated by multiple mechanisms. XAP2/AIP (ARA9) increases cytosolic AhR levels and modifies agonist signaling, thereby influencing the amount of complex available for activation. Phosphodiesterases link the complex to cyclic nucleotide signaling, providing a layer of regulation through second messengers. Ligand binding itself triggers transformation and release of HSP90, which is a key regulatory step for nuclear translocation and target gene induction. Emerging evidence on biased agonism suggests that different ligands can differentially regulate AhR signaling outcomes, adding further complexity to how the cytosolic complex is controlled.
cytosolic aryl hydrocarbon receptor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AHR | Dioxin toxicity, cancer, immune dysregulation | AHR knockout and point-mutation cell lines |
| AIP | Modulation of AhR signaling in disease | AIP knockout or overexpression models |
| CYP1A1 | Xenobiotic metabolism, biomarker of exposure | CYP1A1 reporter knock-in |
| PLA2G4A | Lipid signaling in TCDD response | PLA2G4A knockout in Hepa-1c1c7 cells |
| SRC | Signaling crosstalk in cancer | SRC knockout and kinase-dead knock-in |
Dioxin Toxicity and Environmental Disease
The cytosolic aryl hydrocarbon receptor complex mediates the toxic effects of dioxins such as TCDD, which are widespread environmental contaminants. Activation of AhR by dioxins leads to altered gene expression, including induction of CYP1A1, and contributes to a range of toxic responses. Understanding the ligand-free cytosolic complex is essential for interpreting how dioxins initiate these effects.
Cancer and Cell Proliferation
AhR signaling has been implicated in cancer, where it can influence cell proliferation, survival, and differentiation. The cytosolic aryl hydrocarbon receptor complex is the starting point for these signaling events, and its components, such as XAP2/AIP, may modulate cancer-relevant AhR activity. Emerging approaches to antagonize AhR are being explored as potential anticancer strategies.
Immune and Metabolic Regulation
AhR is a key regulator of immune responses and metabolic pathways, and the cytosolic complex controls the availability of AhR for activation. Biased agonism in AhR signaling can lead to distinct immune or metabolic outcomes, highlighting the importance of the cytosolic complex in disease contexts. Targeting the complex or its regulators may offer therapeutic opportunities.
From cytosolic aryl hydrocarbon receptor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AhR abolish cytosolic complex formation? | AHR knockout cell line |
| How does XAP2/AIP regulate cytosolic AhR levels? | AIP knockout or overexpression |
| What is the role of c-Src in the complex? | SRC point mutation (kinase-dead) or knockout |
| How does ligand binding transform the complex? | Tagged knock-in of AHR for imaging |
| Which genes are induced downstream of complex activation? | RNA-seq after TCDD treatment in wild-type and KO |
| Can biased agonists differentially activate AhR? | Overexpression of AHR with ligand panels |
How to Study the cytosolic aryl hydrocarbon receptor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Velocity sedimentation | Size of cytosolic AhR complex (9S) | Confirmation of ligand-free complex |
| Immunoprecipitation/Western blot | Protein-protein interactions in the complex | Detection of AhR, HSP90, c-Src, XAP2/AIP |
| Ligand binding assay | Affinity and specificity of ligands | Characterization of agonists/antagonists |
| Transformation assay | Conversion to nuclear AhR | Testing ligand-induced activation |
| RNA-seq/qPCR | Target gene induction (e.g., CYP1A1) | Downstream signaling readout |
| CRISPR knockout | Loss-of-function of complex components | Causal gene studies |
| CRISPR knock-in | Tagged or mutant proteins | Imaging and functional studies |
| Overexpression | Gain-of-function of AhR or regulators | Biased agonism studies |
Biochemical Isolation of the Cytosolic Complex
The cytosolic aryl hydrocarbon receptor complex can be studied by biochemical fractionation and velocity sedimentation, historically identified as the 9S complex. Immunoprecipitation of AhR followed by immunoblotting for HSP90, c-Src, and XAP2/AIP can confirm complex composition.
Ligand Binding and Transformation Assays
Ligand binding assays using radiolabeled or fluorescent ligands, combined with transformation assays, measure the conversion of the cytosolic complex to its nuclear form. These methods are used to test agonists such as TCDD and alpha-naphthoflavone.
Gene Expression Analysis
RNA-seq and qPCR for AhR target genes such as CYP1A1 and PLA2G4A are used to assess downstream effects of cytosolic complex activation. These approaches are standard in Hepa-1c1c7 and other AhR-responsive cell lines.
CRISPR-Based Genetic Perturbation
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of AHR, AIP, SRC, and other complex components to test their roles in cytosolic complex function and signaling.
How CRISPR Can Be Used to Study GO:0034752 cytosolic aryl hydrocarbon receptor complex
Knockout
CRISPR knockout of AHR, AIP, SRC, or HSP90 genes can abolish or destabilize the cytosolic aryl hydrocarbon receptor complex, allowing researchers to test its requirement for ligand-induced signaling and target gene induction. Knockout of AIP specifically can reveal its role in modulating cytosolic AhR levels.
Point Mutation
Point mutations can be introduced into AHR to dissect ligand-binding domains or into SRC to abrogate kinase activity, providing fine-grained mechanistic insights into complex function. Such models help distinguish structural from catalytic roles of complex components.
Knock-in
Knock-in of epitope tags or fluorescent proteins into AHR or AIP enables live-cell imaging and biochemical tracking of the cytosolic complex. Tagged knock-in models are valuable for studying complex assembly and transformation dynamics.
Overexpression
Overexpression of AHR or its regulators such as XAP2/AIP can increase cytosolic complex abundance and enhance signaling, useful for studying biased agonism and ligand sensitivity. Overexpression models also facilitate biochemical purification of the complex.
How EDITGENE Supports cytosolic aryl hydrocarbon receptor complex Research
Researchers studying cytosolic aryl hydrocarbon receptor complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, ligand responsiveness, or downstream signaling. EDITGENE provides CRISPR-based cell model services to enable such causal studies with high precision.
Contact EDITGENE today to design your custom CRISPR model for cytosolic aryl hydrocarbon receptor complex research.
Frequently Asked Questions About cytosolic aryl hydrocarbon receptor complex
What is the cytosolic aryl hydrocarbon receptor complex?
It is a cytosolic assembly of AhR, two HSP90 molecules, c-Src, and XAP2/AIP in which AhR is not bound to ligand, defined as GO:0034752.
What genes are involved in the cytosolic aryl hydrocarbon receptor complex?
Key genes include AHR, HSP90AA1, HSP90AB1, SRC, and AIP (XAP2/ARA9).
What is the function of GO:0034752?
It maintains AhR in a stable, ligand-free state in the cytosol, ready for ligand binding and subsequent nuclear signaling.
How is the cytosolic aryl hydrocarbon receptor complex activated?
Ligand binding, such as by TCDD or alpha-naphthoflavone, triggers transformation, release of HSP90, and nuclear translocation of AhR.
What role does XAP2/AIP play in the complex?
XAP2/AIP (ARA9) modifies agonist signaling by increasing cytosolic AhR levels and influencing complex abundance.
Is the cytosolic aryl hydrocarbon receptor complex linked to disease?
Yes, it mediates dioxin toxicity and is implicated in cancer, immune, and metabolic disorders.
How can CRISPR be used to study GO:0034752?
CRISPR knockout, point mutation, knock-in, and overexpression can dissect the roles of AHR, AIP, SRC, and other components.
What methods are used to study the cytosolic AhR complex?
Velocity sedimentation, immunoprecipitation, ligand binding, transformation assays, RNA-seq, and CRISPR screens are commonly used.
What is the 9S-cytosolic aryl hydrocarbon receptor complex?
It is a synonym for the ligand-free cytosolic AhR complex, named for its sedimentation coefficient.
Why is the cytosolic aryl hydrocarbon receptor complex important for toxicology?
It is the initial target of dioxins and related environmental contaminants, mediating their toxic effects.
Conclusion
The cytosolic aryl hydrocarbon receptor complex (GO:0034752) is a defined multiprotein assembly that holds AhR in a ligand-free, responsive state in the cytosol. Its components, including HSP90, c-Src, and XAP2/AIP, regulate AhR stability and signaling, with crosstalk to cyclic nucleotide pathways. Understanding this complex is essential for mechanistic studies of dioxin toxicity, AhR-targeted therapeutics, and disease biology. CRISPR-based models offer powerful tools to dissect the causal roles of each component in this complex.
References
- 1. Dvořák Z et al.. 2025. Emerging approaches for antagonizing the aryl hydrocarbon receptor.. Trends Pharmacol Sci 46(7):629-637 PMID: 40480842
- 2. de Oliveira SK et al.. 2009. Phosphodiesterases link the aryl hydrocarbon receptor complex to cyclic nucleotide signaling.. Biochem Pharmacol 77(4):723-33 PMID: 18805402
- 3. LaPres JJ et al.. 2000. ARA9 modifies agonist signaling through an increase in cytosolic aryl hydrocarbon receptor.. J Biol Chem 275(9):6153-9 PMID: 10692406
- 4. Bock KW. 1994. Aryl hydrocarbon or dioxin receptor: biologic and toxic responses.. Rev Physiol Biochem Pharmacol 125:1-42 PMID: 7984872
- 5. Kinehara M et al.. 2009. Aryl hydrocarbon receptor-mediated induction of the cytosolic phospholipase A(2)alpha gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse hepatoma Hepa-1c1c7 cells.. J Biosci Bioeng 108(4):277-81 PMID: 19716514
- 6. Poellinger L. 2000. Mechanistic aspects--the dioxin (aryl hydrocarbon) receptor.. Food Addit Contam 17(4):261-6 PMID: 10912240
- 7. Dvořák Z et al.. 2026. The landscape of biased agonism in aryl hydrocarbon receptor signaling: current clues and future directions.. Front Pharmacol 17:1823615 PMID: 42222174
- 8. Santostefano M et al.. 1993. alpha-Naphthoflavone-induced CYP1A1 gene expression and cytosolic aryl hydrocarbon receptor transformation.. Mol Pharmacol 43(2):200-6 PMID: 8381508
